CINGULATE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.57 USD | -14.93% |
|
-19.72% | -92.55% |
| 05-21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
| 05-08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CINGULATE INC. | Other Biotechnology & Medical Research | -14.93% | -19.72% | -92.55% | -96.60% | - | 3.94M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- CING Stock
- Charts Cingulate Inc.
- Comparison Chart
